TriSalus Life Sciences, Inc.
TLSI
$6.45
-$0.55-7.86%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.15% | 22.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.15% | 22.32% | |||
| Cost of Revenue | 5.77% | 20.54% | |||
| Gross Profit | 2.65% | 22.67% | |||
| SG&A Expenses | 5.29% | 9.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.97% | 12.42% | |||
| Operating Income | -22.94% | -0.04% | |||
| Income Before Tax | -30.33% | 20.05% | |||
| Income Tax Expenses | 266.67% | -160.00% | |||
| Earnings from Continuing Operations | -30.44% | 20.12% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.44% | 20.12% | |||
| EBIT | -22.94% | -0.04% | |||
| EBITDA | -23.50% | -0.14% | |||
| EPS Basic | -317.51% | 40.92% | |||
| Normalized Basic EPS | -13.62% | 18.59% | |||
| EPS Diluted | -317.51% | 40.92% | |||
| Normalized Diluted EPS | -13.62% | 18.59% | |||
| Average Basic Shares Outstanding | 30.52% | 15.64% | |||
| Average Diluted Shares Outstanding | 30.52% | 15.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||